Immunogenicity of recombinant human interleukin-3

被引：11

作者：

Gunn, H ^{[1
]}

机构：

[1] SANDOZ PHARMA AG,E HANOVER,NJ

来源：

CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY | 1997年 / 83卷 / 01期

关键词：

D O I：

10.1006/clin.1996.4302

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Most recombinant human (rh) proteins elicit an immune response in experimental animals. Antibodies are usually detected within 1 to 2 weeks of protein administration. The immunogenicity of rh proteins is an important aspect for both experimental and clinical investigations. The formation of neutralizing antibodies-as shown here for rhIL-3-reduced the absolute bioavailability of the protein in Rhesus monkeys. (C) 1997 Academic Press.

引用

页码：5 / 7

页数：3

共 8 条

[1]

BORRADORI AG, 1994, STEM CELLS S1, V12, P241

[2]

KRIGEL RL, 1988, CANCER RES, V48, P3875

[3] CLINICAL TOXICITY OF INTERFERONS IN CANCER-PATIENTS - A REVIEW [J].

QUESADA, JR ;

TALPAZ, M ;

RIOS, A ;

KURZROCK, R ;

GUTTERMAN, JU .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (02) :234-243

[4] INDUCTION OF ANTI-RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (ESCHERICHIA COLI-DERIVED) ANTIBODIES AND CLINICAL EFFECTS IN NONIMMUNOCOMPROMISED PATIENTS [J].

RAGNHAMMAR, P ;

FRIESEN, HJ ;

FRODIN, JE ;

LEFVERT, AK ;

HASSAN, M ;

OSTERBORG, A ;

MELLSTEDT, H .

BLOOD, 1994, 84 (12) :4078-4087

[5]

REINER G, 1993, INT REV EXP PATHOL, V34, P119

[6]

ROBISON RL, 1993, INT REV EXP PATHOL, V34, P149

[7]

STAHL CP, 1992, BLOOD, V80, P2479

[8] HUMAN IL-3 (MULTI-CSF) - IDENTIFICATION BY EXPRESSION CLONING OF A NOVEL HEMATOPOIETIC GROWTH-FACTOR RELATED TO MURINE IL-3 [J].

YANG, YC ;

CIARLETTA, AB ;

TEMPLE, PA ;

CHUNG, MP ;

KOVACIC, S ;

WITEKGIANNOTTI, JS ;

LEARY, AC ;

KRIZ, R ;

DONAHUE, RE ;

WONG, GG ;

CLARK, SC .

CELL, 1986, 47 (01) :3-10

← 1 →